News

Fructose sweeteners drive metabolic dysregulation

Publish date: March 25, 2013

 

AT THE ADA ADVANCED POSTGRADUATE COURSE

Dr. Stanhope reported having no financial disclosures.

Pages

Recommended Reading

HDL-raising: A good hypothesis gone bad
MDedge Endocrinology
FDA approves alogliptin, alone and in combinations
MDedge Endocrinology
Injectable 'antisense' drug approved for familial hypercholesterolemia
MDedge Endocrinology
FDA withholds insulin degludec approval; wants safety data
MDedge Endocrinology
Critics dub JNC-8 as 'JNC-Late'
MDedge Endocrinology
Everolimus approval now includes prevention of liver transplant rejection
MDedge Endocrinology
TERISA targets diabetes as potential new market for ranolazine
MDedge Endocrinology
Intense statin therapy treats atheromas in diabetes
MDedge Endocrinology
Lipid metabolism genes linked to breast cancer subtype
MDedge Endocrinology
Being postmenopausal doubles hepatic steatosis risk
MDedge Endocrinology